FAR2P1: A Potential Drug Target and Biomarker for Obesity, Diabetes and Cardiovascular Disease

Target Name: FAR2P1

NCBI ID: G440905

FAR2P1

Other Name(s): Fatty acyl-CoA reductase 2 pseudogene 1 | HEL-182 | fatty acyl-CoA reductase 2 pseudogene 1

FAR2P1: A Potential Drug Target and Biomarker for Obesity, Diabetes and Cardiovascular Disease

FAR2P1, also known as Fatty acyl-CoA reductase 2 pseudogene 1, is a gene that encodes a protein involved in the metabolism of fatty acids. The encoded protein is a key player in the fatty acid oxidation pathway, a critical process that generates energy from the body's fatty acids. This protein is also involved in the regulation of lipid metabolism and has been linked to various diseases, including obesity, diabetes, and cardiovascular disease. As a result, FAR2P1 has emerged as a promising drug target and a biomarker for several diseases.

The Fatty acid oxidation pathway is a critical metabolic pathway that generates energy from the body's fatty acids. This pathway involves the breakdown of fatty acids into acetyl-CoA (acetyl-CoA), which is then used to produce energy in the form of ATP. The FAR2P1 protein is involved in the second step of this pathway, known as the 尾-oxidation step. In this step, the 尾-hydroxyacyl-CoA (尾-hydroxyacetyl-CoA) is converted into the more potent 尾-hydroxyacyl-CoA esters , which can then be converted into fat.

FAR2P1 has been shown to play a crucial role in the regulation of lipid metabolism. It has been shown to promote the oxidation of fatty acids, which is essential for the body to produce energy from the fatty acids. In addition, FAR2P1 has been shown to regulate the synthesis of fatty acids from the diet. This protein has been shown to enhance the body's ability to break down fatty acids from food, which is essential for maintaining energy homeostasis.

The FAR2P1 gene has also been linked to several diseases, including obesity, diabetes, and cardiovascular disease. Obesity is a growing public health issue that is associated with various chronic diseases, including diabetes, cardiovascular disease, and certain cancers. FAR2P1 has been shown to be involved in the regulation of obesity, as it has been shown to play a role in the metabolism of abdominal fat.

In addition, FAR2P1 has also been linked to diabetes. Diabetes is a chronic disease that is characterized by high levels of blood sugar and is associated with a range of complications, including cardiovascular disease, neuropathy, and kidney disease. FAR2P1 has been shown to be involved in the regulation of insulin sensitivity and inflammation, both of which are important factors in the development and progression of diabetes.

FAR2P1 has also been linked to cardiovascular disease. Cardiovascular disease is a leading cause of death and disability in adults and is associated with a range of factors, including obesity, diabetes, and high blood pressure. FAR2P1 has been shown to be involved in the regulation of blood pressure and cholesterol levels, which are critical factors in the development and progression of cardiovascular disease.

In conclusion, FAR2P1 is a gene that encodes a protein involved in the metabolism of fatty acids and has been linked to several diseases, including obesity, diabetes, and cardiovascular disease. As a result, FAR2P1 has emerged as a promising drug target and a biomarker for these diseases. Further research is needed to fully understand the role of FAR2P1 in the development and progression of these diseases and to develop effective treatments.

Protein Name: Fatty Acyl-CoA Reductase 2 Pseudogene 1

The "FAR2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAR2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets